In advance of World AIDS Day on December 1st, the HIV+Hepatitis Policy Institute has released a report modeling the resources needed to fund a national Pre-Exposure Prophylaxis (PrEP) program.
The U.S. House of Representatives Labor, HHS Appropriations Subcommittee is proposing to increase funding to continue to ramp up efforts to end HIV in the United States. However, it fails to include a national program to increase access to PrEP, which are medications that prevent HIV. In addition to an increase of $225 million for domestic HIV testing, prevention, and treatment programs as part of the Ending the HIV Epidemic initiative, the FY23 Labor, HHS appropriations bill is proposing a $75 million increase to the Ryan White HIV/AIDS Program and $200 million more for NIH AIDS Research.
President Biden is proposing an increase of $377 million for the Ending the HIV Epidemic in the U.S. initiative for a total of $850 million for efforts to end HIV by 2030. Additionally, in response to the HIV community and several members of Congress’ request to develop a program to increase access to PrEP, which are medications that prevent HIV, the president’s budget calls for the creation of an ambitious ten-year $9.8 billion nationwide PrEP delivery program. The budget includes numerous other program increases, including a bump of $13.5 million for the CDC’s hepatitis division.
In the omnibus appropriations bill released today, Congress has significantly slowed the increase of funding for the Ending the HIV Epidemic in the U.S. initiative and put in jeopardy efforts to end HIV by 2030. Instead of supporting an increase of $245 million, as was proposed in President Biden’s budget and passed by the House and proposed by Senate Democratic leaders, the final bill allocates an increase of only $70 million for HIV testing, prevention, treatment, and research programs for those jurisdictions most impacted by HIV.
Today, PrEP4ALL with HIV+Hepatitis Policy Institute submitted a letter of over 60 signatures of leading HIV organizations calling on the Centers for Disease Control & Prevention (CDC) and the White House Office of National AIDS Policy (ONAP) to request the CDC to reverse its decision to prohibit the use of CDC prevention funds to pay for the additional costs of PrEP, including provider visits, labs for screening and monitoring.